Loading
Latest filing published 22 Sept 2022 for Medexus Pharmaceuticals Inc. (formerly Pediapharm Inc.), €19k.
No signal scores available.
All filings by Michael David Adelman on record concern Medexus Pharmaceuticals Inc. (formerly Pediapharm Inc.). We count 3 filings; the first trade dates from 1 May 2020 and the latest from 22 September 2022.
No open-market sale appears; the market trades are 2 purchases worth €25k. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Since January 2022: 2 purchases and no sales on the market.
The record was last updated on 22 September 2022 with an open-market purchase (€19k) in Medexus Pharmaceuticals Inc. (formerly Pediapharm Inc.). Filings reach the SEDI feed a median of 1 day after the trade. The shorter that gap, the sooner other investors can see what insiders have done. Source: insider filings from SEDI. Past trades are no guide to future returns.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
3 of 3 declarations